FDA Expands Approved Use of Kalydeco to Treat Additional Mutations of Cystic Fibrosis

May 17, 2017 -- The U.S. Food and Drug Administration today expanded the approved use of Kalydeco (ivacaftor) for treating cystic fibrosis. The approval triples the number of rare gene mutations that the drug can now treat, expanding the indication...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news